Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
Police say violent crime improving in downtown Raleigh, but more work is needed
Recommended
Back to school guide: Buses, lunches, key dates
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Apellis Pharmaceuticals Inc
(NQ:
APLS
)
37.25
-0.37 (-0.98%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Apellis Pharmaceuticals Inc
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
16
17
Next >
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
June 02, 2023
Big Pharma is facing a patent cliff that could siphon off billions in revenue.
Via
Investor's Business Daily
Apellis Pharma Flunks On Primary, Secondary Endpoints In Amyotrophic Lateral Sclerosis Study
May 25, 2023
Via
Benzinga
Apellis Pharmaceuticals Inc. (NASDAQ: APLS) is a Stock Spotlight on 5/25
May 25, 2023
Via
Investor Brand Network
Needham Maintains Buy Rating for Apellis Pharmaceuticals: Here's What You Need To Know
May 05, 2023
Via
Benzinga
Top-Notch Biotech Apellis Soars After New Drug Obliterates Sales Views
May 05, 2023
The company easily beat sales calls on the back of Syfovre, a geography atrophy drug.
Via
Investor's Business Daily
Why Shares of Annexon Are Plummeting Thursday
May 25, 2023
Mixed trial results on a geographic atrophy eye drug led investors to sell the biotech stock.
Via
The Motley Fool
Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS
May 25, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Why These 3 Nasdaq Stocks Buckled Today
May 16, 2023
The FTC's decision to sue to block a high-profile merger is weighing on biotech valuations today.
Via
The Motley Fool
Are Small Caps a Harbinger of Market Declines?
May 09, 2023
The iShares Russell 2000 ETF outperformed the S&P 500 last week, but that may be short-lived. Small-cap momentum is often a bellwether for broad-market action.
Via
MarketBeat
Topics
ETFs
Stocks
Exposures
US Equities
The Latest Analyst Ratings for Apellis Pharmaceuticals
May 05, 2023
Via
Benzinga
Apellis Pharmaceuticals: Q1 Earnings Insights
May 04, 2023
Via
Benzinga
Earnings Preview: Apellis Pharmaceuticals
May 03, 2023
Via
Benzinga
Wedbush Maintains Neutral Rating for Apellis Pharmaceuticals: Here's What You Need To Know
April 17, 2023
Via
Benzinga
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 05, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharma's Newly Approved Drug Exceeds Sales Projections, Bullish Analyst Raises Expectations
May 05, 2023
Apellis Pharmaceuticals Inc (NASDAQ: APLS) reported Q1 revenues of $44.8 million, surpassing the consensus of $26.10 million and
Via
Benzinga
Apellis Pharmaceuticals Reports First Quarter 2023 Financial Results
May 04, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
9 Analysts Have This to Say About Apellis Pharmaceuticals
April 14, 2023
Via
Benzinga
Apellis Pharmaceuticals to Present at the Bank of America Securities 2023 Healthcare Conference
May 03, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today
May 01, 2023
These three biotech stocks were on the volatile side today.
Via
The Motley Fool
Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma
May 01, 2023
The company is working on a treatment for the eye disease known as geographic atrophy.
Via
Investor's Business Daily
Top 5 Health Care Stocks That Could Sink Your Portfolio This Quarter
April 27, 2023
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Via
Benzinga
Apellis Pharmaceuticals to Host Conference Call on May 4, 2023, to Discuss First Quarter 2023 Financial Results
April 27, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
April 26, 2023
Via
Benzinga
Apellis Presents Phase 3 Functional Analyses of SYFOVRE™ (pegcetacoplan injection) for Geographic Atrophy
April 23, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy
April 21, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
April 19, 2023
Via
Benzinga
Apellis Partners with Acclaimed Actor Henry Winkler to Raise Awareness of Geographic Atrophy (GA) for the GA Won’t Wait™ Campaign
April 17, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
April 12, 2023
Via
Benzinga
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 06, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.